These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 16641470)

  • 1. In vitro activities of DX-619 and four comparator agents against 376 anaerobic bacterial isolates.
    Molitoris D; Väisänen ML; Bolaños M; Finegold SM
    Antimicrob Agents Chemother; 2006 May; 50(5):1887-9. PubMed ID: 16641470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative in vitro activity of BAY 12-8039 and five other antimicrobial agents against anaerobic bacteria.
    Edlund C; Sabouri S; Nord CE
    Eur J Clin Microbiol Infect Dis; 1998 Mar; 17(3):193-5. PubMed ID: 9665302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of Bay 12-8039, a new 8-methoxyquinolone, compared to the activities of 11 other oral antimicrobial agents against 390 aerobic and anaerobic bacteria isolated from human and animal bite wound skin and soft tissue infections in humans.
    Goldstein EJ; Citron DM; Hudspeth M; Hunt Gerardo S; Merriam CV
    Antimicrob Agents Chemother; 1997 Jul; 41(7):1552-7. PubMed ID: 9210683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro antianaerobic activity of DX-619, a new des-fluoro(6) quinolone.
    Tanaka K; Mikamo H; Nakao K; Watanabe K
    Antimicrob Agents Chemother; 2006 Nov; 50(11):3908-13. PubMed ID: 17065629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
    Lee Y; Park Y; Kim MS; Yong D; Jeong SH; Lee K; Chong Y
    Antimicrob Agents Chemother; 2010 Sep; 54(9):3993-7. PubMed ID: 20585132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the in vitro activities of Bay 12-8039, a new quinolone, and other antimicrobials against clinically important anaerobes.
    Aldridge KE; Ashcraft DS
    Antimicrob Agents Chemother; 1997 Mar; 41(3):709-11. PubMed ID: 9056020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activities of moxifloxacin against 900 aerobic and anaerobic surgical isolates from patients with intra-abdominal and diabetic foot infections.
    Edmiston CE; Krepel CJ; Seabrook GR; Somberg LR; Nakeeb A; Cambria RA; Towne JB
    Antimicrob Agents Chemother; 2004 Mar; 48(3):1012-6. PubMed ID: 14982797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of spores on the comparative efficacies of five antibiotics for treatment of Bacillus anthracis in an in vitro hollow fiber pharmacodynamic model.
    Louie A; VanScoy BD; Brown DL; Kulawy RW; Heine HS; Drusano GL
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1229-39. PubMed ID: 22155821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ciprofloxacin- and methicillin-resistant staphylococcus aureus susceptible to moxifloxacin, levofloxacin, teicoplanin, vancomycin and linezolid.
    Presterl E; Mueller-Uri P; Grisold A; Georgopoulos A; Graninger W
    Eur J Clin Microbiol Infect Dis; 2001 Jul; 20(7):486-9. PubMed ID: 11561805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis.
    Rodríguez JC; Ruiz M; López M; Royo G
    Int J Antimicrob Agents; 2002 Dec; 20(6):464-7. PubMed ID: 12458143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of BAY 12-8039, a new fluoroquinolone.
    Woodcock JM; Andrews JM; Boswell FJ; Brenwald NP; Wise R
    Antimicrob Agents Chemother; 1997 Jan; 41(1):101-6. PubMed ID: 8980763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative in-vitro activities of moxifloxacin, trovafloxacin, quinupristin/dalfopristin and linezolid against staphylococci.
    von Eiff C; Peters G
    J Antimicrob Chemother; 1999 Apr; 43(4):569-73. PubMed ID: 10350389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of DX-619 compared to other agents against viridans group streptococci, Streptococcus bovis, and Cardiobacterium hominis.
    Kosowska-Shick K; Smith K; Bogdanovich T; Ednie LM; Jones RN; Appelbaum PC
    Antimicrob Agents Chemother; 2006 Dec; 50(12):4191-4. PubMed ID: 17043120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative in vitro antimicrobial activity of a novel quinolone, garenoxacin, against aerobic and anaerobic microbial isolates recovered from general, vascular, cardiothoracic and otolaryngologic surgical patients.
    Edmiston CE; Krepel CJ; Kehl KS; Seabrook GR; Somberg LB; Almassi GH; Smith TL; Loehrl TA; Brown KR; Lewis BD; Towne JB
    J Antimicrob Chemother; 2005 Nov; 56(5):872-8. PubMed ID: 16186167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activities of DX-619 and comparison quinolones against gram-positive cocci.
    Wickman PA; Black JA; Moland ES; Thomson KS
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2255-7. PubMed ID: 16723599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of pulmonary surfactant on antimicrobial activity in vitro.
    Schwameis R; Erdogan-Yildirim Z; Manafi M; Zeitlinger MA; Strommer S; Sauermann R
    Antimicrob Agents Chemother; 2013 Oct; 57(10):5151-4. PubMed ID: 23877678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antipneumococcal activity of DW-224a, a new quinolone, compared to those of eight other agents.
    Kosowska-Shick K; Credito K; Pankuch GA; Lin G; Bozdogan B; McGhee P; Dewasse B; Choi DR; Ryu JM; Appelbaum PC
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2064-71. PubMed ID: 16723567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recently introduced antibiotics: a guide for the general physician.
    Wiselka M
    Clin Med (Lond); 2004; 4(6):494-8. PubMed ID: 15656473
    [No Abstract]   [Full Text] [Related]  

  • 19.
    Goldstein EJC; Citron DM; Tyrrell KL; Leoncio ES
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28373186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. E test susceptibility testing of nosocomial Clostridium difficile isolates against metronidazole, vancomycin, fusidic acid and the novel agents moxifloxacin, gatifloxacin, and linezolid.
    Leroi MJ; Siarakas S; Gottlieb T
    Eur J Clin Microbiol Infect Dis; 2002 Jan; 21(1):72-4. PubMed ID: 11913510
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.